All In Biotech

Drug Trial Radar · NCT05736835

A Phase 2 Trial of the Immunogenicity and Safety of CVXGA Intranasal COVID Vaccine in Healthy Adults

Last checked: Nov 19, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 227 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

227

Actual

Start

Sep 21, 2023

Primary completion

Dec 16, 2025

Study completion Dec 16, 2025

Sponsor

Lead sponsor
CyanVac LLCIndustry
Sponsor type
Industry
First posted
Feb 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Single group
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this trial is to evaluate immunogenicity and safety of CVXGA administered as a single intranasal dose against SARS-CoV-2 S-protein in participants. The trial will enroll up to 400 healthy participants, age 18-80 years.

Conditions

  • COVID-19

Interventions

  • CVXGABiological

    CVXGA is a live viral vector, consisting of a recombinant parainfluenza virus type 5 that carries the SARS-CoV-2 S-protein from WA.1 (not enrolling) or XBB1.5 strain.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety outcome measures (SAEs, AEs, and local and systemic reactogenicity)Time frame: day 1-8, day 1-29, and day 1-181 post vaccination
  2. ImmunogenicityTime frame: day 15 and day 29

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Velocity Clinical Research

    San Diego, California

  • Velocity Clinical Research

    Boise, Idaho

  • Velocity Clinical Research

    Sioux City, Iowa

  • Velocity Clinical Research

    Rockville, Maryland

  • Velocity Clinical Research

    Omaha, Nebraska

  • University of Rochester

    Rochester, New York

  • Velocity Clinical Research

    Vestal, New York

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Velocity Clinical Research

    Providence, Rhode Island

  • Velocity Clinical Research

    Cedar Park, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.